English
This article is from Indian Journal of Ophthalmology , volume 62 . Abstract Introduction:: Diabetic macular edema (DME) is a vision-threatening complication of diabetic retinopathy. The current practice of management is a trial and error method of using intravitreal antivascular endothelial growth factor (VEGF)” or steroids to treat the patient and watch the response. However, if the patient's genetic profile helps us choose appropriate medicine, it would help customize treatment option for each patient. This forms the basis of our study. Materials and Methods:: A case-control, prospective, observational series, where DME patients were treated with bevacizumab and subclassified as treatment naοve, treatment responders, and treatment nonresponders. Blood samples of 20 subjects were studied, with five patients in each of the groups (nondiabetic- group 1, treatment naοve- group 2, treatment responder- group 3, and treatment nonresponder-group 4). Whole blood RNA extraction followed by labeling, amplification and hybridization was done, and microarray data analyzed. Genes were classified based on functional category and pathways. Results:: The total number of genes upregulated among al
Sign in with your free account to read, download EPUBs or listen.
Ebook · Differential systemic gene expression profile in patients with diabetic macular edema: Responders versus nonresponders to standard treatment. · Dabir, Supriya S, Das, Debashish, Nallathambi, Jeyabalan, Mangalesh, Shwetha, Yadav, Naresh Kumar, Schouten, Jan S A G · Internet Archive